Estimated Time
1.25 hrs
Release Date
Oct 07, 2024
Expiration Date
Oct 06, 2025
This educational activity is derived from three Plenary Sessions held at the twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024), originally presented on September 4-7, 2024.
Speakers
Ching-Hon Pui, MD
Chair, Department of Oncology
St. Jude Children's Research Hospital
Memphis, TN, USA
Ching-Hon Pui, M.D. is the Chair of the Department of Oncology at St. Jude Children’s Research Hospital, Memphis, Tennessee, and an American Cancer Society Professor.
He pioneered the use of precision medicine in pediatric cancer treatment based on minimal residual disease, cancer genetics and host pharmacogenetics. He also led research that showed prophylactic cranial irradiation could be omitted in all patients without reducing survival rates for pediatric acute lymphoblastic leukemia.
Dr. Pui’s work helped push the cure rate of acute lymphoblastic leukemia, the most common childhood cancer, above 90% and improved the quality of life of survivors. He has formed two national and international study groups and organized major annual national and international teaching conferences to promote research and extend the curative treatment globally.
He has published over 1000 articles and is one of the most highly cited researchers. For his significant contributions to the field of pediatric oncology, he has been honored with many prestigious awards, professorships and degree including elected fellow of American Association for the Advancement of Science, and membership to the American Society of Clinical Investigation, Association of American Physicians, Academia Sinica (Taiwan) and Chinese Academy of Engineering.
John Seymour, MBBS, FRACP, PhD
Director, Cancer Medicine
Director, Department of Haematology
Peter MacCallum Cancer Centre
Melbourne, Australia
Professor John Seymour AM is a clinical haematologist and Associate Director of Clinical Research at the Peter MacCallum Centre, and the Director of the integrated Haematology Department of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital in Melbourne, Australia.
He received his MB, BS degrees from the University of Melbourne in 1987, completed a translational research fellowship at the MD Anderson Cancer Center in Houston, and subsequently received their Distinguished Alumnus award in 2011. He also completed PhD studies in the pathobiology of haematopoietic growth factors at the Ludwig Institute for Cancer Research. Professor Seymour is a member of several national and international scientific committees including, Cancer Australia Advisory Groups, the Scientific Advisory Committee for the International Conference on Malignant Lymphoma, Medical Advisory Board of the Lymphoma Coalition, and the Board of Directors of the International Extranodal Lymphoma Study Group.
He served for more than a decade as Executive member and Chairman of the major national clinical trials co-operative group in haematologic malignancies, the Australasian Leukaemia & Lymphoma Group. He is a frequent invited speaker nationally and internationally, is a member of numerous professional societies, an Editor-in-Chief of Leukemia & Lymphoma, and currently on the editorial boards of Blood and the British Journal of Haematology.
He has authored 18 book chapters, >500 peer reviewed publications (with >25,000 literature citations), and >700 conference abstracts. Actively involved in a broad range of collaborative research, Professor Seymour has been the principal investigator on >85 clinical trials and chief investigator on competitive grants awarded >AUD$18 million funding in the last 10 years. In 2015 he was awarded Membership of the Order of Australia and elected to the Australian Academy of Health and Medical Sciences for his contributions to the field.
Conference highlights:
'BT-199 (GDC-0199) in relapsed/refractory leukemia and small lymphocytic leukemia and lymphoma: high response rates among patients with high risk disease features including unmutated IGHV,'19th Congress of the European Hematology Association, Tuesday 17 June 2014. 'Promising CLL treatments: a Bcl-2inhibitorupdate',Patient Power, Friday 21 February 2014. 'Dr John Seymour on the efficacy of ABT-199 in high-risk CLL', American Society of Hematology Annual Meeting and Exposition, Sunday 8 December 2013.
Valeria Santini, MD
Associate Professor of Hematology
University of Florence
Florence, Italy
Valeria Santini is Associate Professor of Hematology at the University of Florence, Italy. She runs the MDS Unit- Hematology- Department of Experimental and Clinical Medicine- AOU Careggi, University of Florence. Her interests are focused on clinical and translational research in MDS and elderly AML. Professor Santini is President of the Scientific Committee of Fondazione Italiana per lo studio delle sindromi mielodisplastiche (FISiM) and Italian Network of MDS Registries. She belongs to ASH, EHA SOHO, AA&MDS International Foundation and MDS Foundation.
She is also an author of more than 250 peer-reviewed papers published in international journals, she is member of the Editorial board of Leukemia Journal and has been member of the Editorial board of Blood journal, and documented reviewer for high impact factor scientific journals. She has been an invited speaker at numerous international meetings including the American Society of Clinical Oncology (ASCO 2007: educational session on MDS, ASCO 2023 educational session), American Society of Hematology (ASH 2012, ASH 2016: educational sessions on MDS, ASH 2023 Educational Spotlights), European Haematology Association (EHA 2016, EHA 2020, EHA 2022: Educational sessions on MDS) and national haematology societies of several countries.
Accreditation and Disclosure Information
Target Audience
This CE activity is directed towards physicians, fellows, nurses, physician associates, pharmacists, and students interested in Hematology Oncology, Medical Oncology and Internal Medicine.
Agenda
- Enhancing Precision Treatment for Childhood Acute Lymphoblastic Leukemia | Ching-Hon Pui, MD, St. Jude Children's Research Hospital, Memphis, TN, USA
- BCL2 Inhibition in CLL: From Undruggable Target to Standard of Care | John Seymour, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia
- Myelodysplastic Neoplasms and the Challenge of Therapeutic Targets: Genetics, Epigenetics, or Inflammation? | Valeria Santini, MD, University of Florence, Florence, Italy
Educational Objectives
After completing this activity, the participant should be better able to:
- Apply recent national guidelines to guide individualized treatment selection for various blood cancers, focusing on the integration of the latest clinical safety and efficacy data.
- Differentiate between the advantages and disadvantages of various treatment modalities, including frontline and second-line treatments, CAR T and bispecific therapies, JAK inhibitors, and TKIs, considering individual patient characteristics and needs.
- Optimize patient assessment by incorporating genetic, biomarker testing, frailty assessments, and consideration of individual characteristics, to ensure effective, individualized patient care.
Jointly provided by:
Accreditation and Credit Statements
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and The Society of Hematologic Oncology. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
ECMEC® Credit
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)™. into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).
PA
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until October 6, 2025. PAs should only claim credit commensurate with the extent of their participation.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-24-083-H01-P
Type of Activity: Knowledge
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.25 contact hours.
Support Statement
There is no commercial support associated with this activity.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. and The Society of Hematologic Oncology are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Presenter
Ching-Hon Pui, MD
Chair, Department of Oncology
St. Jude Children's Research Hospital
Memphis, TN, USA
Ching-Hon Pui, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Adaptive Biotech, Amgen, Novartis
Presenter
Valeria Santini, MD
Associate Professor of Hematology
University of Florence
Florence, Italy
Valeria Santini, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Bristol Myers Squibb, CTI, Curis, Geron, Gilead, Keros, Menarini, Novartis, Servier, Syros
Speakers' Bureau: Bristol Myers Squibb
Presenter
John Seymour, MBBS, FRACP, PhD
Director, Cancer Medicine
Director, Department of Haematology
Peter MacCallum Cancer Centre
Melbourne, Australia
John Seymour, MBBS, FRACP, PhD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Genor Bio, Gilead, Janssen, Roche
Research Grant: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Roche
Speakers' Bureau: AbbVie, AstraZeneca, Bristol Myers Squibb, Roche
Independent Contractor: Genor Biopharma
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and The Society of Hematologic Oncology, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board. If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/
About This Activity
Medical Learning Institute, Inc. and The Society of Hematologic Oncology are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. and The Society of Hematologic Oncology.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute, Inc | All Rights Reserved